Stifel raised the firm’s price target on Boston Scientific (BSX) to $120 from $115 and keeps a Buy rating on the shares after having hosted ...

In addition, technological advancements such as the increasing use of AI, predictive analysis, and advanced algorithms are ...

Barclays raised the firm’s price target on Boston Scientific (BSX) to $118 from $111 and keeps an Overweight rating on the shares. The firm ...

Quantum computing, long relegated to the realm of the theoretical, feels like it is back on the agenda as a potentially ...

Stifel analysts increased their price target on Boston Scientific Corporation (NYSE:BSX) shares from $115.00 to $120.00, while reiterating a Buy rating for the medical device company. The adjustment ...

Momentum investing revolves around the idea of following a stock's recent trend in either direction. In the 'long' context, investors will be essentially be "buying high, but hoping to sell even ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

His next chance to suit up will come Wednesday against San Antonio, which is Boston's final contest before the All-Star break. Tatum is questionable for Monday's game against the Heat due to right ...

February 6, 2025 • Today: Chuck Todd, formerly of NBC News, discusses the media's ability to hold Trump accountable. Senator Ed Markey discusses the Democratic opposition. Best Of BPR 2/05 ...

Tillman was not on Boston's initial injury report, so this is apparently a new issue for the forward. Tillman has played just six minutes in one February appearance, however, so this news won't ...